Publications

You are here

Home » Research Groups » Cancer molecular targets » Publications

Dianes moleculars del Càncer

Electrochemical immunosensing of st2: A checkpoint target in cancer diseases

Torrente-Rodríguez, R.M.;Martín, C.M.S.;Gamella, M.;Pedrero, M.;Martínez-Bosch, N.;Navarro, P.;de Frutos, P.G.;Pingarrón, J.M.;Campuzano, S,
2021

CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington¿s disease

Picó S, Parras A, Santos-Galindo M, Pose-Utrilla J, Castro M, Fraga E, Hernández IH, Elorza A, Anta H, Wang N, Martí-Sánchez L, Belloc E, Garcia-Esparcia P, Garrido JJ, Ferrer I, Macías-García D, Mir P, Artuch R, Pérez B, Hernández F, Navarro P, López-Sen,
2021

Prognostic value of VEGFR2 immunoexpression in glioblastoma

Issus G, Mojal S, Gibert J, Navarro P, Arumi-Uria M, Naranjo-Hans D, Bellosillo B, Martínez-Garcia M, Alameda F,
2020

Knockdown of α2,3-Sialyltransferases Impairs Pancreatic Cancer Cell Migration, Invasion and E-selectin-Dependent Adhesion

Guerrero PE, Miró L, Wong BS, Massaguer A, Martínez-Bosch N, Llorens R, Navarro P, Konstantopoulos K, Llop E, Peracaula R.,
2020

Impact of Galectins in Resistance to Anticancer Therapies.

- Navarro P, Martínez-Bosch N, Blidner AG, Rabinovich GA.,
2020

Galectins in the Tumor Microenvironment: Focus on Galectin-1

Martínez-Bosch N, Navarro P.,
2020

The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic Cancer

Manero-Rupérez N, Martínez-Bosch N, Barranco LE, Visa L, Navarro P.,
2020

Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities

Martínez-Bosch N, Rodriguez-Vida A, Juanpere N, Lloreta J, Rovira A, Albanell J, Bellmunt J, Navarro P,
2019

Autism-like phenotype and risk gene mRNA deadenylation by CPEB4 mis-splicing.

Parras A, Anta H, Santos-Galindo M, Swarup V, Elorza A, Nieto-González JL, Picó S, Hernández IH, Díaz-Hernández JI, Belloc E, Rodolosse A, Parikshak NN, Peñagarikano O, Fernández-Chacón R, Irimia M, Navarro P, Geschwind DH, Méndez R, Lucas JJ,
2019

Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker

Martinez-Bosch N, Barranco LE, Orozco CA, Moreno M, Visa L, Iglesias M, Oldfield L, Neoptolemos JP, Greenhalf W, Earl J, Carrato A, Costello E, Navarro P. ,
2019

Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy

Martinez-Bosch N, Vinaixa J, Navarro P.,
2018

Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk

Orozco CA, Martinez-Bosch N, Guerrero PE, Vinaixa J,Dalotto-Moreno T, Iglesias M, Moreno M, Djurec M, Poirier F, Gabius HJ, Fernandez-Zapico ME, Hwang RF, Guerra C, Rabinovich GA, Navarro P,
2018

Translational reprogramming in tumor cells can generate oncoselectivity in viral therapies.

Villanueva E, Navarro P, Rovira-Rigau M, Sibilio A, Méndez R, Fillat C (,
2017

A novel translational control mechanism involving RNA structures within coding sequences

Jungfleisch J, Nedialkova DD, Dotu I, Sloan KE, Martinez-Bosch N, Brüning L, Raineri E, Navarro P, Bohnsack MT, Leidel SA, Díez ,
2017

Poly(ADP-Ribose) Polymerases: New Players in the Pathogenesis of Exocrine Pancreatic Diseases.

Martínez-Bosch N, Fernández-Zapico ME, Navarro P, Yélamos J.,
2016

Snail1 is required for the maintenance of the pancreatic acinar phenotype.

Loubat-Casanovas J, Peña R, Gonzàlez N, Alba-Castellón L, Rosell S, Francí C, Navarro P, García de Herreros A.,
2016

The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.

Martínez-Bosch N, Guerrero PE, Moreno M, José A, Iglesias M, Munné-Collado J, Anta H, Gibert J, Orozco CA, Vinaixa J, Fillat C, Viñals F, Navarro P.,
2016

Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease

Calderone V, Gallego J, Fernandez-Miranda G, Garcia-Pras E, Maillo C, Berzigotti A, Mejias M, Bava FA, Angulo-Urarte A, Graupera M, Navarro P, Bosch J, Fernandez M, Mendez R. ,
2016

Targeting Galectin-1 in pancreatic cancer: immune surveillance on guard.

Martínez-Bosch N & Navarro P. ,
2014

Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation.

Martínez-Bosch N, Fernández-Barrena MG, Moreno M, Ortiz-Zapater E, André S, Gabius H-J, Hwang RF, Poirier F, Munné-Collado J, Iglesias M, Navas C, Guerra C, Fernández-Zapico ME and Navarro P. ,
2014

Pages